
Loading, please wait...

Loading, please wait...

The 2026 Surviving Sepsis Campaign guideline update reflects how rapidly sepsis management has evolved since the previous international recommendations. The guideline addresses recognition and diagnosis, antimicrobial therapy, source control, haemodynamic management, vasopressors, organ support, nutrition, corticosteroids, glucose control and post-intensive care considerations. For clinicians, the value of the update is less about one new intervention and more about integrating a large and changing evidence base into a practical framework. The 2026 document incorporates contemporary evidence on fluid strategies, dynamic assessment of perfusion, antimicrobial timing and de-escalation, vasopressor use, corticosteroids and organ support. It also places greater emphasis on context, patient heterogeneity and implementation. This directly aligns with the conference's focus on evolving definitions, precision care, personalised resuscitation, antibiotic stewardship and guideline implementation. A key practical lesson is that sepsis care should be dynamic: reassess perfusion, treatment response, infection source and organ function repeatedly rather than treating the initial presentation as a fixed state. For HCPs, the guideline is best used as a structured decision framework, combined with bedside physiology and clinical judgement. It is especially relevant when translating international evidence into resource-variable ICU practice.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


The 2026 Surviving Sepsis Campaign guideline update reflects how rapidly sepsis management has evolved since the previous international recommendations. The guideline addresses recognition and diagnosis, antimicrobial therapy, source control, haemodynamic management, vasopressors, organ support, nutrition, corticosteroids, glucose control and post-intensive care considerations. For clinicians, the value of the update is less about one new intervention and more about integrating a large and changing evidence base into a practical framework. The 2026 document incorporates contemporary evidence on fluid strategies, dynamic assessment of perfusion, antimicrobial timing and de-escalation, vasopressor use, corticosteroids and organ support. It also places greater emphasis on context, patient heterogeneity and implementation. This directly aligns with the conference's focus on evolving definitions, precision care, personalised resuscitation, antibiotic stewardship and guideline implementation. A key practical lesson is that sepsis care should be dynamic: reassess perfusion, treatment response, infection source and organ function repeatedly rather than treating the initial presentation as a fixed state. For HCPs, the guideline is best used as a structured decision framework, combined with bedside physiology and clinical judgement. It is especially relevant when translating international evidence into resource-variable ICU practice.
Today

The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back

A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back

Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back

A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back

A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back